Search | Clinical Trials Finder

Conditions: Osteoarthritis of Knee
Interventions: Cryopreserved Devitalized Adipose Tissue Allograft, Normal Saline (Placebo); Biological · Other
Lead sponsor: Britecyte; Network
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 7
States / cities: Baltimore, Maryland • Hagerstown, Maryland • Oxon Hill, Maryland + 4 more

Conditions: Osteoarthritis, Knee, Pain
Interventions: V116517 50-mg tablets, V116517 30-mg tablets, Naproxen 500-mg capsules, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Tucson, Arizona • Boynton Beach, Florida • DeLand, Florida + 13 more

Conditions: Osteoarthritis of the Knee
Interventions: FX006 10 mg, FX006 40 mg, TCA IR 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Paducah, Kentucky • Duncansville, Pennsylvania • Dallas, Texas

Conditions: Osteoarthritis
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 26
States / cities: Phoenix, Arizona • Tempe, Arizona • Huntington Beach, California + 22 more

Conditions: Osteoarthritis, Knee
Interventions: PF-04457845, Naproxen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Miami, Florida • Overland Park, Kansas • San Antonio, Texas

Conditions: Chronic Pain, Osteoarthritis
Interventions: transcranial direct current stimulation (tDCS), transcranial ultrasound (TUS); Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis (OA) of the Knee
Interventions: Enekinragene Inzadenovec (PCRX-201), Placebo; Biological
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 34 more

Conditions: Osteoarthritis (OA) of the Knee
Interventions: Triamcinolone Acetonide, 0.9% Sodium Chloride Injection as Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 45 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis
Interventions: Canakinumab, Placebo to canakinumab, Naproxen, Placebo to Naproxen; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Anniston, Alabama • Mesa, Arizona • San Diego, California + 5 more

Conditions: Osteoarthritis (OA) of the Hip, Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Shoulder, Osteoarthritis, Mild Cognitive Impairment, MCI, Mild Cognitive Impairment (MCI), Dementia
Interventions: Well-formulated ketogenic diet; Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 55 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Fairway, Kansas

Conditions: Lower-limb Orthoses, Osteoarthritic Knee Pain, Osteoarthritis (OA) of the Knee
Interventions: Modular powered orthosis; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 85 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Osteoarthritis of the Knee
Interventions: FX006 32 mg, TCA IR 40; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Canoga Park, California • San Diego, California • Hialeah, Florida + 1 more

Conditions: Osteoarthritis
Interventions: Diclofenac Sodium gel, 1%, Voltaren® Gel, Placebo; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 35 Years and older
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 44
States / cities: Mesa, Arizona • Anaheim, California • Canoga Park, California + 32 more

Conditions: Osteoarthritis
Interventions: Buprenorphine transdermal patch; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 42
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more

Conditions: Osteoarthritis, Pain
Interventions: Placebo, Fulranumab 1 mg, Fulranumab 3 mg, Opioid; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 36
States / cities: Birmingham, Alabama • Huntsville, Alabama • Cerritos, California + 33 more

Conditions: Osteoarthritis of the Knee
Interventions: Amniotic Fluid 4.0ml dose, Amniotic Fluid 2.0ml dose, Placebo Control; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Birmingham, Alabama • Des Plaines, Illinois

Conditions: Osteoarthritis of the Knee
Interventions: ketoprofen in Diractin®, Placebo; Drug
Lead sponsor: IDEA AG; Industry
Eligibility: 46 Years and older
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 37
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 32 more

Conditions: Osteoarthitis, Osteoarthritic Knee Pain, Osteoarthritis (OA), Osteoarthritis (OA) of the Knee, Osteoarthritis in the Knee
Interventions: Anteromedial Injection, Anterolateral Injection; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Bolingbrook, Illinois • Chicago, Illinois • La Grange, Illinois + 2 more

Conditions: Osteoarthritis of the Knee
Interventions: TLC599, DSP, Normal Saline; Drug · Other
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 40 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 33 more

Conditions: Osteoarthritis of the Knee
Interventions: Cooled Radiofrequency, Standard Radiofrequency; Device
Lead sponsor: Avanos Medical; Other
Eligibility: 21 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Altoona, Pennsylvania • Sewickley, Pennsylvania • State College, Pennsylvania + 4 more

Conditions: Degenerative Osteoarthritis
Interventions: TG-C, Placebo Control; Biological
Lead sponsor: Kolon TissueGene, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Osteoarthritis (OA) of the Knee, Fear of Needles
Interventions: 25 gauge needle, 22 gauge needle, +/- Ethyl Chloride Topical Aerosol Anesthetic; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 40 Years to 89 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Knee Osteoarthritis
Interventions: Knee Brace + OPUM Digital Knee, Knee Brace; Device
Lead sponsor: OPUM Technologies US LTD; Other
Eligibility: 40 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoarthritis, Pain
Interventions: Placebo, Fulranumab 1 mg, Fulranumab 3 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Phoenix, Arizona • Costa Mesa, California • Laguna Hills, California + 23 more

Search by objective public record fields.

A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee

Effects of tDCS and tUS on Pain Perception in OA of the Knee

A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee

Effect of Steroid Injections in a Knee With Osteoarthritis

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

Ketogenic Diet to Reduce Osteoarthritis Pain in MCI

Enhancing Voluntary Motion in Broad Patient Populations With Modular Powered Orthoses Renewal

Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee

To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).

Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase

Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001

Evaluation of Amniotic Fluid Product in Knee Osteoarthritis

Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee

Patient Pain and Function in Medial Knee Osteoarthritis After Anteromedial vs Anterolateral Intra-Articular Corticosteroid Injection

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

Coolief Cooled Radiofrequency vs. Conventional Radiofrequency to Manage OA Knee Pain

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

Pain Perception During Intra-Articular Knee Joint Injection: What is the Effect of Needle Gauge and the Use of Ethyl Chloride?

Impact of Sensor Technology in Knee OA

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002